Schonfeld Strategic Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-203,680
| Closed | -$4.11M | – | 2802 |
|
|
2021
Q3 | $4.11M | Buy |
203,680
+158,795
| +354% | +$4.38M | 0.04% | 491 |
|
|
2021
Q2 | $1.68M | Buy |
44,885
+8,883
| +25% | +$272K | 0.02% | 769 |
|
|
2021
Q1 | $920K | Buy |
36,002
+21,064
| +141% | +$538K | 0.01% | 932 |
|
|
2020
Q4 | $330K | Sell |
14,938
-44,806
| -75% | -$987K | ﹤0.01% | 1174 |
|
|
2020
Q3 | $1.07M | Buy |
59,744
+36,312
| +155% | +$752K | 0.02% | 682 |
|
|
2020
Q2 | $595K | Buy |
+23,432
| New | +$505K | 0.02% | 746 |
|
|
2020
Q1 | – | Sell |
-10,036
| Closed | -$221K | – | 1658 |
|
|
2019
Q4 | $221K | Sell |
10,036
-35,864
| -78% | -$722K | 0.01% | 1126 |
|
|
2019
Q3 | $659K | Sell |
45,900
-117,800
| -72% | -$1.68M | 0.02% | 571 |
|
|
2019
Q2 | $2.58M | Buy |
+163,700
| New | +$2.23M | 0.09% | 249 |
|
|
2019
Q1 | – | Sell |
-85,900
| Closed | -$918K | – | 1380 |
|
|
2018
Q4 | $918K | Sell |
85,900
-192,400
| -69% | -$2.53M | 0.04% | 497 |
|
|
2018
Q3 | $4.25M | Buy |
278,300
+233,300
| +518% | +$3.4M | 0.19% | 154 |
|
|
2018
Q2 | $551K | Sell |
45,000
-51,268
| -53% | -$644K | 0.03% | 519 |
|
|
2018
Q1 | $921K | Buy |
+96,268
| New | +$1.04M | 0.07% | 339 |
|
Other funds holding DRNA
Schonfeld Strategic Advisors's DRNA Position: Q4 2021 in Review
Schonfeld Strategic Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 203,680 shares — an estimated $4.11M sold.
Schonfeld Strategic Advisors first reported a position in DRNA in Q1 2018 and held it in 13 quarters. The position peaked at $4.25M in Q3 2018. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Schonfeld Strategic Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Schonfeld Strategic Advisors sold 203,680 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4.11M.
- Schonfeld Strategic Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 13 quarters.
- Schonfeld Strategic Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $4.25M in Q3 2018.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.